Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 03'rd Jan 2023
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
03:53pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
02:40pm, Thursday, 22'nd Dec 2022 Zacks Investment Research
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year?
11:18am, Thursday, 22'nd Dec 2022
Here is how Intra-Cellular Therapies (ITCI) and RxSight, Inc. (RXST) have performed compared to their sector so far this year.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
02:51pm, Wednesday, 21'st Dec 2022 Zacks Investment Research
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro e
Intra-Cellular: Hitting A Growth Inflection (Rating Upgrade)
09:30am, Sunday, 18'th Dec 2022
Following approval for schizophrenia in late 2019, Caplyta then gained its first label expansion for bipolar depression. As Caplyta is serving a much larger market, sales growth has hit an inflection
Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?
02:40pm, Wednesday, 30'th Nov 2022 Zacks Investment Research
Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.
Axsome: Strong Earnings Signal More Upside
07:40am, Thursday, 24'th Nov 2022 Seeking Alpha
As Auvelity is recently approved, Axsome now has two solid drugs that are likely to generate significant market traction. Read what this means for AXSM stock.
Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?
02:55pm, Wednesday, 23'rd Nov 2022 Zacks Investment Research
The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Can Intra-Cellular (ITCI) Climb 33% to Reach the Level Wall Street Analysts Expect?
11:17am, Wednesday, 23'rd Nov 2022
The consensus price target hints at a 32.7% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
06:38pm, Friday, 18'th Nov 2022 Zacks Investment Research
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in sever
Intra-Cellular's (ITCI) Caplyta Aids Growth, Overdependence a Woe
03:11pm, Friday, 18'th Nov 2022
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in sever
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
08:08pm, Monday, 07'th Nov 2022 Zacks Investment Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
How Much Upside is Left in Intra-Cellular (ITCI)? Wall Street Analysts Think 33%
11:21am, Monday, 07'th Nov 2022
The consensus price target hints at a 33.5% upside potential for Intra-Cellular (ITCI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Intra-Cellular Therapies, Inc. (ITCI) Q3 2022 Earnings Call Transcript
02:42pm, Thursday, 03'rd Nov 2022
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Co-Found
